Novartis AG
Nucleic acids encoding lectin-like oxidized LDL receptor 1 antibodies
Last updated:
Abstract:
The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as "LOX-1"), and pharmaceutical compositions and methods of treatment comprising the same.
Status:
Grant
Type:
Utility
Filling date:
4 May 2018
Issue date:
22 Dec 2020